دورية أكاديمية
أعرض في EDS

Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1

التفاصيل البيبلوغرافية
العنوان: Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1
المؤلفون: Uğur Yayla, Mehmet Orkun Sevik, Veysel Levent Karabaş, Özlem Şahin, Abdullah Özkaya, Nursal Melda Yenerel, Banu Açıkalın Öncel, Fatih Bilgehan Kaplan, Ecem Önder Tokuç, Hatice Selen Kanar, Işıl Kutlutürk Karagöz, Ece Başaran Emengen, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Özlem Aydın Öncü, Esra Türkseven Kumral, Nimet Yeşim Erçalık, Erkan Çelik
المصدر: Türk Oftalmoloji Dergisi, Vol 53, Iss 6, Pp 356-368 (2023)
بيانات النشر: Galenos Yayinevi, 2023.
سنة النشر: 2023
المجموعة: LCC:Medicine
LCC:Ophthalmology
مصطلحات موضوعية: anti-vegf, diabetic macular edema, intravitreal injection, real-life study, routine clinical practice, Medicine, Ophthalmology, RE1-994
الوصف: Objectives: This study aimed to report the demographic and clinical characteristics of diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGF) and provide an overview of outcomes during routine clinical practice in Türkiye. Materials and Methods: This retrospective, real-world study included 1,372 eyes (854 patients) treated with a pro re nata protocol by 21 ophthalmologists from 8 tertiary clinics on the Asian side of the Marmara region of Türkiye (MARMASIA Study Group). Five cohort groups were established by collecting the patients’ baseline and 3, 6, 12, 24, and 36-month follow-up data, where each subsequent cohort may include the previous. Changes in best-corrected visual acuity (BCVA, approximate ETDRS letters) and central macular thickness (CMT, μm), number of visits and IVI, and rates of anti-VEGF switch and intravitreal dexamethasone implant (IDI) combination were evaluated. Results: The 3, 6, 12, 24, and 36-month cohorts included 1372 (854), 1352 (838), 1185 (722), 972 (581), and 623 (361) eyes (patients), respectively. The mean baseline BCVA and CMT were 51.4±21.4 letters and 482.6±180.3 μm. The mean changes from baseline in BCVA were +7.6, +9.1, +8.0, +8.6, and +8.4 letters, and in CMT were -115.4, -140.0, -147.9, -167.3, and -215.4 μm at the 3, 6, 12, 24, and 36-month visits (p
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
Turkish
تدمد: 1300-0659
2147-2661
Relation: http://www.oftalmoloji.org/archives/archive-detail/article-preview/real-world-outcomes-of-ntravitreal-anti-vascular-e/63937; https://doaj.org/toc/1300-0659; https://doaj.org/toc/2147-2661
DOI: 10.4274/tjo.galenos.2023.56249
URL الوصول: https://doaj.org/article/366bac1877524f1aba6d51d5c33e7bbc
رقم الأكسشن: edsdoj.366bac1877524f1aba6d51d5c33e7bbc
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:13000659
21472661
DOI:10.4274/tjo.galenos.2023.56249